(Q33393763)

English

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase III clinical trial

0 references

object named as

Lars Bastholt

3

0 references

author name string

Johan Hansson

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Steinar Aamdal

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yvonne Brandberg

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Micaela Hernberg

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Bo Nilsson

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ulrika Stierner

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hans von der Maase

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Nordic Melanoma Cooperative Group

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

20 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

144-152

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970288-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970288-6

7 January 2021

based on heuristic

inferred from DOI database lookup

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970288-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970288-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple Hypothesis Testing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970288-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970288-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970288-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970288-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970288-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970288-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970288-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(10)70288-6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33393763&oldid=1638278955"